Human study maps epoxy-oxylipin pathway that helps turn off inflammation
A human study found that epoxy-oxylipins help regulate inflammation and that GSK2256294 increased these molecules, reduced pain faster and lowered intermediate monocytes. The findings map epoxy-oxylipin activity in humans during inflammation.
Researchers identified a biological process that helps the body shut down inflammation once it is no longer needed. The study, published in Nature Communications, found that small fat-based molecules known as epoxy-oxylipins act as natural regulators of the immune response. Using GSK2256294 to block soluble epoxide hydrolase increased levels of epoxy-oxylipins, reduced pain faster, and lowered levels of intermediate monocytes in blood and tissue.
Researchers conducted a carefully controlled experiment in healthy volunteers who received a small injection of UV-killed E. coli bacteria in the forearm. This triggered a temporary inflammatory response, including pain, redness, heat and swelling. Volunteers were divided into a prophylactic arm and a therapeutic arm.
In the prophylactic arm, 24 volunteers participated; 12 received the drug and 12 received placebo two hours before inflammation began. In the therapeutic arm, another 24 volunteers; 12 treated and 12 untreated with placebo; received the drug four hours after inflammation had started.
In both groups, blocking soluble epoxide hydrolase increased levels of epoxy-oxylipins. Participants who received the drug experienced faster pain resolution and had significantly lower levels of intermediate monocytes, the immune cells linked to chronic inflammation and disease. The medication did not meaningfully change visible symptoms such as redness or swelling.
Further investigation showed that one specific epoxy-oxylipin, 12,13-EpOME, works by suppressing p38 MAPK, a protein signaling pathway that drives monocyte transformation. Laboratory experiments and additional testing in volunteers who received a p38 blocking drug confirmed this mechanism.
Scientists chose to investigate epoxy-oxylipins because previous animal research suggested they can reduce inflammation and pain, but their role in human biology had not been clearly defined. The study described this as the first to map epoxy-oxylipin activity in humans during inflammation and said the findings open the possibility of clinical trials to test whether boosting these protective fat molecules could help treat flares in chronic inflammatory conditions.